- Cigna’s adjusted revenue for the second quarter is reported at $67.13 billion, marking an 11% increase year-over-year and surpassing the expectation of $62.38 billion.
- Evernorth’s adjusted revenues for the same period reached $57.83 billion, a 17% growth year-over-year, exceeding the forecast of $53.9 billion.
- Cigna Healthcare reported adjusted revenues of $10.75 billion, showing an 18% decline year-over-year.
- The adjusted operating earnings per share (EPS) is $7.20, which is higher than the previous year’s $6.72 and exceeds the estimate of $7.15.
- Cigna Healthcare’s medical care ratio increased slightly to 83.2% compared to 82.3% last year, and is below the expected 83.4%.
- Pharmacy revenue experienced a significant rise, reaching $53.65 billion, indicating a 19% increase from the previous year.
- Premiums collected decreased by 20% year-over-year, totaling $9.16 billion.
- The number of global medical customers has declined by 5.2% to 18.05 million, although it remains above the estimate of 17.98 million.
- The forecast for the year anticipates an adjusted operating EPS of at least $29.60, slightly below the estimated $29.66.
- Cigna maintains its forecast for the Cigna Healthcare medical care ratio between 83.2% and 84.2%, against an estimate of 83.8%.
- Evernorth’s adjusted income from operations is expected to be no less than $7.20 billion pre-tax.
- Cigna Healthcare’s adjusted income from operations is projected to be at least $4.13 billion pre-tax.
“`
Cigna Group on Smartkarma
Analyst coverage of Cigna Group on Smartkarma shows a positive sentiment from Baptista Research. In their report titled “Cigna Group: Broad Suite of GLP-1 Solutions to Innovate & Lead In Addressing Contemporary Healthcare Challenges Efficiently!” the analysts highlight Cigna’s robust performance in the first quarter of 2025. With total revenues of $65.5 billion and adjusted earnings per share of $6.74, the company has demonstrated strong growth. Cigna also raised its full-year EPS guidance to at least $29.60, signaling optimism for future performance.
Furthermore, Baptista Research‘s report “Cigna Group: Strategic Growth & Capital Investments Driving Our Optimism!” discusses the company’s fourth-quarter and full-year 2024 financial results. Despite a mixed performance, Cigna saw a 27% increase in full-year revenue to approximately $247 billion, indicating strong revenue growth. However, adjusted earnings per share (EPS) only rose by 9% to $27.33, below expectations and suggesting some pressure on profitability. Overall, analysts at Baptista Research remain bullish on Cigna Group, emphasizing the strategic growth and capital investments propelling their optimism for the company’s future.
A look at Cigna Group Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analyzing the Smartkarma Smart Scores for Cigna Group, the company appears to have a well-rounded long-term outlook. With consistent scores of 3 across various factors including Value, Dividend, Growth, Resilience, and Momentum, Cigna Group seems to be positioned steadily in the market. This suggests that the company maintains a balanced approach, offering a competitive mix of value, growth potential, and stability. Investors may find Cigna Group to be a reliable choice for potential long-term growth and returns.
As an insurance company catering to a global clientele, the Cigna Group provides a range of insurance products and services, including life, accident, disability, medicare, and dental coverage. This diversified offering indicates the company’s commitment to meeting the needs of individuals, families, and businesses worldwide. With consistent scores reflecting across key factors, Cigna Group‘s outlook points towards a stable and resilient position in the insurance market, potentially appealing to investors seeking a well-rounded investment opportunity.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
